Related references
Note: Only part of the references are listed.Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial
Patrice Carde et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study
Armando Santoro et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study
Pier Luigi Zinzani et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Margaretha G. M. Roemer et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
Anas Younes et al.
LANCET ONCOLOGY (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation
Miguel-Angel Perales et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
Nikolaos Patsoukis et al.
NATURE COMMUNICATIONS (2015)
PD-1 Restrains Radiotherapy-Induced Abscopal Effect
Sean S. Park et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Serum Thymus and Activation-Regulated Chemokine Level Monitoring May Predict Disease Relapse Detected by PET Scan after Reduced-Intensity Allogeneic Stem Cell Transplantation in Patients with Hodgkin Lymphoma
Lucia Farina et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma
Ryan D. Gentzler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Anti-PD1 antibody: a new approach to treatment of lymphomas
Emmanuel Bachy et al.
LANCET ONCOLOGY (2014)
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
Jason R. Westin et al.
LANCET ONCOLOGY (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
Tobias Bald et al.
CANCER DISCOVERY (2014)
Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma
Maike Sauer et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome
Yago Nieto et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496
Andrew M. Evens et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
Philippe Armand et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
Anas Younes et al.
LANCET ONCOLOGY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
Michael R. Green et al.
CLINICAL CANCER RESEARCH (2012)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
Andreas Engert et al.
LANCET (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
PD-1 Expression on Natural Killer Cells and CD8+ T Cells During Chronic HIV-1 Infection
Sonia Norris et al.
VIRAL IMMUNOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
Michael R. Green et al.
BLOOD (2010)
PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1
Marguerite Ghiotto et al.
INTERNATIONAL IMMUNOLOGY (2010)
Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial
Hans Theodor Eich et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma
Andreas Engert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation
Asad Bashey et al.
BLOOD (2009)
Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
Stephen M. Ansell et al.
CLINICAL CANCER RESEARCH (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma
Ryo Yamamoto et al.
BLOOD (2008)
Managing relapsed and refractory Hodgkin lymphoma
Pauline Brice
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies
Raanan Berger et al.
CLINICAL CANCER RESEARCH (2008)
Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: Tumor and microenvironment
Eric D. Hsi
LEUKEMIA & LYMPHOMA (2008)
RNA fingerprints provide direct evidence for the inhibitory role of TGFβ and PD-1 on CD4+ T cells in Hodgkin lymphoma
Jens M. Chemnitz et al.
BLOOD (2007)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver
JC Lavoie et al.
BLOOD (2005)
Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse
A Sureda et al.
ANNALS OF ONCOLOGY (2005)
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells
C Blank et al.
CANCER RESEARCH (2004)
Hodgkin's disease in the elderly: a population-based study
GL Stark et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience)
I Radman et al.
ANNALS OF ONCOLOGY (2002)
Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-κB
S Mathas et al.
EMBO JOURNAL (2002)
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease:: a randomised trial
N Schmitz et al.
LANCET (2002)
Share Paper
